Skip to content
Clinical Research Made Simple

Clinical Research Made Simple

Trusted Resource for Clinical Trials, Protocols & Progress

  • Home
  • Audit Findings
    • General Audit Findings in Clinical Trials
    • Investigator Site-Level Audit Findings
    • Sponsor & CRO-Level Audit Findings
    • Trial Master File (TMF) & eTMF Audit Findings
    • Informed Consent Audit Findings
    • Safety Reporting Audit Findings
    • Data Integrity & EDC Audit Findings
    • GCP Training & Compliance Audit Findings
    • Clinical Trial Supply & IMP Audit Findings
    • Ethics Committee / IRB Audit Findings
    • CAPA & Inspection Readiness Audit Findings
    • Case Studies & Trends in Audit Findings
  • Audits, CAPA & Deviations
    • CRO Audit Oversight
    • CAPA Management in CROs
    • Deviation Handling in CROs
    • Inspection Readiness for CROs
    • Data Integrity & Systems Oversight
    • Training & Quality Culture in CROs
  • SOPs for GCP
    • Global SOPs (Applicable to all Agencies)
    • SOP for IDE/Device
    • FDA — Unique SOPs (United States)
    • EMA — Unique SOPs (European Union)
    • CDSCO/DCGI – Unique SOPs (India)
    • WHO – Unique SOPs
    • ICH – Unique SOPs
    • MHRA — Unique SOPs (United Kingdom)
    • Health Canada — Unique SOPs (Canada)
    • PMDA — Unique SOPs
    • TGA — Unique SOPs
    • NMPA — Unique SOPs
    • ANVISA — Unique SOPs
    • Swiss Medic — Unique SOPs
    • Medsafe/HDEC — Unique SOPs (New Zealand)
  • US Regulatory Submissions
  • Toggle search form

SOP for Insurance and Indemnity Requirements

Posted on August 23, 2025 digi By digi

SOP for Insurance and Indemnity Requirements

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/insurance-and-indemnity-requirements”
},
“@id”: “https://www.clinicalstudies.in/insurance-and-indemnity-requirements”,
“headline”: “SOP for Insurance and Indemnity Requirements”,
“name”: “SOP for Insurance and Indemnity Requirements”,
“description”: “Comprehensive SOP defining insurance and indemnity requirements for clinical trials under TGA oversight, including sponsor responsibilities, site obligations, and compliance with GCP.”,
“keywords”: “insurance requirements clinical trials, indemnity SOP Australia, CTN CTX insurance compliance, trial indemnity requirements TGA, investigator indemnity SOP, site insurance SOP, sponsor insurance obligations Australia, indemnity agreement SOP, TGA trial governance, site indemnity documentation, ethics approval insurance requirements, clinical trial insurance checklist, sponsor indemnification responsibilities, Australian trial insurance SOP, SSA insurance requirements, trial governance indemnity, site indemnity verification SOP, indemnity certificate SOP Australia, insurance policy documentation SOP, subject insurance requirements, insurance compliance Australia, indemnity in CTN CTX schemes, ethics indemnity approval, SOP for indemnity records, trial sponsor insurance QA SOP”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {

/> “@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Published on 22/12/2025

Insurance and Indemnity Requirements SOP

Department Clinical Research
SOP No. CS/TGA-INS/176/2025
Supersedes N.A.
Page No. 1 of 20
Issue Date 28/08/2025
Effective Date 05/09/2025
Review Date 05/09/2027

Table of Contents

Toggle
  • Purpose
  • Scope
  • Responsibilities
  • Accountability
  • Procedure
  • Abbreviations
  • Documents
  • References
  • Approval
  • Annexures
  • Revision History

Purpose

The purpose of this SOP is to establish requirements for insurance and indemnity in clinical trials conducted under the CTN/CTX schemes in Australia. It ensures sponsor, site, and investigator compliance with TGA, Human Research Ethics Committee (HREC), and institutional governance requirements to safeguard participant rights and provide indemnity coverage for clinical trial-related injuries.

See also  SOP for Telemedicine Visits and Remote AE Reporting

Scope

This SOP applies to all clinical trials sponsored or managed by the organization in Australia requiring insurance and indemnity arrangements. It covers sponsor obligations for trial insurance, indemnity agreements with investigators and sites, documentation requirements, and institutional governance compliance. It also applies to multi-site trials requiring SSA documentation of insurance arrangements.

Responsibilities

  • Sponsor: Secures insurance policy covering trial participants for injury or harm related to investigational products and trial procedures.
  • Principal Investigator (PI): Ensures site staff are informed of indemnity arrangements and provides indemnity certificates to site governance offices.
  • Regulatory Affairs (RA): Confirms insurance documents are filed with CTN/CTX submissions and SSA applications.
  • Clinical Project Manager (CPM): Coordinates insurance certificates for each site and maintains tracking logs.
  • Quality Assurance (QA): Audits insurance and indemnity records for inspection readiness.

Accountability

The Sponsor is accountable for ensuring valid insurance and indemnity coverage throughout the trial duration. The Head of Clinical Research is accountable for maintaining oversight of insurance arrangements across all trials.

Procedure

1. Insurance Policy Requirements

  1. Obtain trial insurance policy covering clinical trial liability, participant compensation, and investigator indemnity.
  2. Ensure policy meets Australian law and HREC requirements.
  3. Maintain policy validity throughout the study with no lapses in coverage.

2. Indemnity Agreements

  1. Prepare indemnity agreements for investigators and institutions using Medicines Australia Standard Indemnity templates.
  2. Ensure indemnity agreements are executed before trial initiation at each site.
  3. File signed agreements in TMF and ISF.
See also  SOP for FDA Form 1572 Collection, Updates, and Maintenance

3. Documentation for Ethics and Governance

  1. Submit copies of insurance policies and indemnity agreements with HREC and SSA applications.
  2. Record acknowledgments and approvals in Insurance Documentation Log.

4. Monitoring and Renewals

  1. Monitor policy expiry dates and renew coverage before lapse.
  2. Update insurance certificates for protocol amendments or trial extensions.

5. Archiving

  1. Archive insurance and indemnity documents for a minimum of 15 years or as per institutional requirements.

Abbreviations

  • CTN: Clinical Trial Notification
  • CTX: Clinical Trial Exemption
  • TGA: Therapeutic Goods Administration
  • HREC: Human Research Ethics Committee
  • SSA: Site-Specific Assessment
  • PI: Principal Investigator
  • CPM: Clinical Project Manager
  • RA: Regulatory Affairs
  • QA: Quality Assurance
  • TMF: Trial Master File
  • ISF: Investigator Site File

Documents

  1. Insurance Documentation Log (Annexure-1)
  2. Indemnity Agreement Template (Annexure-2)
  3. Insurance Certificate Tracker (Annexure-3)

References

  • TGA — Clinical Trials Guidance
  • Medicines Australia Standard Indemnity
  • ICH E6(R2) Good Clinical Practice

Version: 1.0

Approval

Prepared By Checked By Approved By
Name: Rajesh Kumar
Date: 20/08/2025
Signature: __________
Name: Sunita Reddy
Date: 22/08/2025
Signature: __________
Name: Dr. Meera Iyer
Date: 28/08/2025
Signature: __________

Annexures

Annexure-1: Insurance Documentation Log

Date Policy No. Coverage Type Expiry Date Status Owner
05/08/2025 POL-2025-01 Clinical Trial Liability 05/08/2026 Active Rajesh Kumar

Annexure-2: Indemnity Agreement Template

Institution Investigator Agreement Type Date Signed
Melbourne General Hospital Dr. Sarah Lee Medicines Australia Standard Indemnity 10/08/2025
See also  SOP for Long-Term Follow-Up (LTFU) of ATMP Subjects

Annexure-3: Insurance Certificate Tracker

Site Certificate No. Issued Date Expiry Date Status
Sydney Clinical Centre IC-2025-07 12/08/2025 12/08/2026 Valid

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
28/08/2025 1.0 Initial SOP for insurance and indemnity requirements. New SOP created for compliance with TGA CTN/CTX governance. Head of Clinical Research

For more SOPs visit: Pharma SOP.

SOP for GCP, TGA — Unique SOPs Tags:Australian trial insurance SOP, clinical trial insurance checklist, CTN CTX insurance compliance, ethics approval insurance requirements, ethics indemnity approval, indemnity agreement SOP, indemnity certificate SOP Australia, indemnity in CTN CTX schemes, indemnity SOP Australia, insurance compliance Australia, insurance policy documentation SOP, insurance requirements clinical trials, investigator indemnity SOP, site indemnity documentation, site indemnity verification SOP, site insurance SOP, SOP for indemnity records, sponsor indemnification responsibilities, sponsor insurance obligations Australia, SSA insurance requirements, subject insurance requirements, TGA trial governance, trial governance indemnity, trial indemnity requirements TGA, trial sponsor insurance QA SOP

Post navigation

Previous Post: SOP for IP Reconciliation and Accountability Logs
Next Post: How to Document and Classify Deviations in CRO Processes

Quick Guide – 1

  • Clinical Trial Phases (7)
    • Preclinical Studies (25)
    • Phase 0 (Microdosing Studies) (6)
    • Phase 1 (Safety and Dosage) (66)
    • Phase 2 (Efficacy and Side Effects) (54)
    • Phase 3 (Confirmation and Monitoring) (70)
    • Phase 4 (Post-Marketing Surveillance) (79)
  • Regulatory Guidelines (71)
    • U.S. FDA Regulations (14)
    • CDSCO (India) Guidelines (11)
    • EMA (European Medicines Agency) Guidelines (17)
    • PMDA (Japan) Guidelines (1)
    • MHRA (UK) Guidelines (1)
    • TGA (Australia) Guidelines (1)
    • Health Canada Guidelines (1)
    • WHO Guidelines (1)
    • ICH Guidelines (12)
    • ASEAN Guidelines (11)
  • Country-Specific Clinical Trials (254)
    • Clinical Trials in USA (51)
    • Clinical Trials in China (49)
    • Clinical Trials in EU (51)
    • Clinical Trials in India (51)
    • Clinical Trials in UK (51)
    • Clinical Trials in Canada (1)
  • Clinical Trial Design and Protocol Development (106)
    • Randomized Controlled Trials (RCTs) (11)
    • Adaptive Trial Designs (10)
    • Crossover Trials (10)
    • Parallel Group Designs (11)
    • Factorial Designs (11)
    • Cluster Randomized Trials (11)
    • Single-Arm Trials (10)
    • Open-Label Studies (11)
    • Blinded Studies (Single, Double, Triple) (11)
    • Non-Inferiority and Equivalence Trials (8)
    • Randomization Techniques in Crossover Trials (1)
  • Good Clinical Practice (GCP) and Compliance (78)
    • GCP Training Programs (11)
    • ICH-GCP Compliance (11)
    • GCP Violations and Audit Responses (11)
    • Monitoring Plans (11)
    • Investigator Responsibilities (11)
    • Sponsor Responsibilities (11)
    • Ethics Committee Roles (11)
  • Clinical Research Operations (44)
    • Study Start-Up Activities (9)
    • Site Selection and Initiation (10)
    • Patient Enrollment Strategies (13)
    • Data Collection and Management (10)
    • Monitoring and Auditing (1)
    • Study Close-Out Procedures (0)
  • Site Management and Monitoring (72)
    • Site Feasibility Assessments (20)
    • Site Initiation Visits (10)
    • Routine Monitoring Visits (10)
    • Source Data Verification (12)
    • Site Close-Out Visits (10)
    • Site Performance Metrics (10)
  • Contract Research Organizations (CROs) (55)
    • Full-Service CROs (11)
    • Functional Service Providers (FSPs) (10)
    • Niche/Specialty CROs (11)
    • CRO Selection Criteria (11)
    • CRO Oversight and Management (11)
  • Patient Recruitment and Retention (57)
    • Recruitment Strategies (11)
    • Retention Strategies (11)
    • Patient Engagement Tools (11)
    • Diversity and Inclusion in Trials (11)
    • Use of Social Media for Recruitment (12)
  • Informed Consent and Ethics Committees (54)
    • Informed Consent Process (11)
    • Ethics Committee Submissions (10)
    • Ethical Considerations in Vulnerable Populations (11)
    • Consent in Emergency Research (10)
    • Re-Consent Procedures (11)
  • Decentralized Clinical Trials (DCTs) (55)
    • Remote Patient Monitoring (10)
    • Telemedicine in Trials (11)
    • Home Health Visits (11)
    • Direct-to-Patient Drug Delivery (11)
    • Digital Consent Platforms (11)
  • Clinical Trial Supply and Logistics (55)
    • Investigational Product Management (11)
    • Cold Chain Logistics (10)
    • Supply Chain Risk Management (11)
    • Labeling and Packaging (11)
    • Return and Destruction of Supplies (11)
  • Safety Reporting and Pharmacovigilance (56)
    • Adverse Event Reporting (11)
    • Serious Adverse Event (SAE) Management (11)
    • Safety Signal Detection (11)
    • Risk Management Plans (11)
    • Periodic Safety Update Reports (PSURs) (11)
  • Clinical Data Management (57)
    • Case Report Form (CRF) Design (11)
    • Data Entry and Validation (11)
    • Query Management (11)
    • Database Lock Procedures (11)
    • Data Archiving (12)
  • Biostatistics in Clinical Research (57)
    • Statistical Analysis Plans (11)
    • Sample Size Determination (11)
    • Interim Analysis (11)
    • Survival Analysis (12)
    • Handling Missing Data (11)
  • Real-World Evidence (RWE) and Observational Studies (56)
    • Registry Studies (11)
    • Retrospective Chart Reviews (11)
    • Prospective Cohort Studies (11)
    • Case-Control Studies (11)
    • Use of Electronic Health Records (EHRs) (11)
  • Medical Writing and Study Documentation (58)
    • Protocol Writing (11)
    • Investigator Brochures (11)
    • Clinical Study Reports (CSRs) (11)
    • Manuscript Preparation (11)
    • Regulatory Submission Documents (13)
  • Trial Master File (TMF) Management (57)
    • TMF Structure and Contents (10)
    • Electronic TMF Systems (7)
    • TMF Quality Control (12)
    • Inspection Readiness (12)
    • Archiving Requirements (11)
  • Protocol Amendments and Version Control (45)
    • Amendment Classification (11)
    • Regulatory Submissions of Amendments (11)
    • Communication of Changes to Sites (11)
    • Version Control Systems (11)
  • Data Integrity and ALCOA+ Principles (46)
    • Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA) (12)
    • Complete, Consistent, Enduring, and Available (ALCOA+) (10)
    • Data Governance Policies (12)
    • Audit Trails (11)
  • Investigator and Site Training (44)
    • Investigator Meetings (11)
    • Site Staff Training Programs (11)
    • Training Documentation (11)
    • Continuing Education Requirements (10)
  • Budgeting and Financial Management (40)
    • Budget Development (10)
    • Site Payment Management (10)
    • Financial Forecasting (10)
    • Cost Tracking and Reporting (10)
  • AI, Big Data, and Technology in Clinical Trials (41)
    • AI in Patient Recruitment (10)
    • Machine Learning for Data Analysis (10)
    • Blockchain for Data Security (10)
    • Wearable Devices and Sensors (11)
  • Career in Clinical Research (52)
    • Clinical Research Coordinator (CRC) Roles (11)
    • Clinical Research Associate (CRA) Roles (10)
    • Data Manager Careers (10)
    • Biostatistician Roles (10)
    • Regulatory Affairs Careers (11)
  • Clinical Trial Registries and Result Disclosure (40)
    • ClinicalTrials.gov Registration (9)
    • EudraCT Registration (10)
    • Results Posting Requirements (10)
    • Transparency Initiatives (11)

Quick Guide – 2

  • Clinical Trial Operations & Data Integrity (31)
    • TMF & eTMF (10)
    • Study Operations & Enrollment (10)
    • Biostats, CDISC & Traceability (11)
  • Clinical Trial Operations & Compliance (54)
    • Clinical Trial Logistics (30)
    • TMF / eTMF Management (6)
    • Clinical Trial Phases & Design (6)
    • Regulatory Submissions (CTD/eCTD) (6)
    • Vendor Oversight & CRO Compliance (6)
  • Quality Assurance and Audit Management (40)
    • Internal Audits (10)
    • External Audits (10)
    • Audit Preparation (10)
    • Corrective and Preventive Actions (CAPA) (10)
  • Risk-Based Monitoring (RBM) (40)
    • Risk Assessment Tools (10)
    • Centralized Monitoring Techniques (10)
    • Key Risk Indicators (KRIs) (10)
    • Key Risk Indicators (KRIs) (10)
  • Standard Operating Procedures (SOPs) (39)
    • SOP Development (9)
    • SOP Training (10)
    • SOP Compliance Monitoring (10)
    • SOP Revision Processes (10)
  • Electronic Data Capture (EDC) and eCRFs (40)
    • EDC System Selection (10)
    • eCRF Design (10)
    • Data Validation Rules (10)
    • User Access Management (10)
  • Wearables and Digital Endpoints (35)
    • Integration of Wearable Devices (10)
    • Digital Biomarkers (9)
    • Data Collection and Analysis (7)
    • Regulatory Considerations (9)
  • Blockchain and Data Security in Trials (39)
    • Blockchain Applications in Clinical Research (10)
    • Data Encryption Methods (9)
    • Access Control Mechanisms (11)
    • Compliance with Data Protection Regulations (9)
  • Biomarkers and Companion Diagnostics (39)
    • Biomarker Identification (10)
    • Validation Processes (10)
    • Companion Diagnostic Development (9)
    • Regulatory Approval Pathways (10)
  • Pediatric and Geriatric Clinical Trials (55)
    • Ethical Considerations (11)
    • Age-Specific Protocol Design (22)
    • Dosing and Safety Assessments (11)
    • Recruitment Strategies (11)
  • Oncology Clinical Trials (54)
    • Phase-Specific Oncology Trials (10)
    • Immunotherapy Studies (14)
    • Biomarker-Driven Trials (10)
    • Basket and Umbrella Trials (8)
    • Cancer Vaccines (12)
  • Vaccine Clinical Trials (40)
    • Phase I–IV Vaccine Trials (10)
    • Immunogenicity Assessments (10)
    • Cold Chain Requirements (10)
    • Post-Marketing Surveillance (10)
  • Rare and Orphan Disease Trials (186)
    • Patient Recruitment Challenges (31)
    • Regulatory Incentives (10)
    • Adaptive Trial Designs (10)
    • Natural History Studies (10)
    • Regulatory Frameworks (22)
    • Trial Design & Methodology (22)
    • Operational Challenges (21)
    • Ethics & Patient Engagement (20)
    • Data & Technology (20)
    • Case Studies & Breakthroughs (20)
  • Bioavailability and Bioequivalence Studies (BA/BE) (41)
    • Study Design Considerations (11)
    • Analytical Method Validation (10)
    • Statistical Analysis Requirements (10)
    • Regulatory Submission (10)
  • Regulatory Submissions and Approvals (73)
    • IND (Investigational New Drug) Submissions (10)
    • CTA (Clinical Trial Application) (10)
    • NDA/BLA/MAA Filings (10)
    • ANDA for Generics (10)
    • eCTD Submission Process (2)
    • Pre-Submission Meetings (FDA Type A/B/C) (10)
    • Regulatory Query Response Handling (10)
    • Post-Approval Commitments (11)
  • Clinical Trial Transparency and Ethics (60)
    • Trial Disclosure Obligations (10)
    • Result Publication Requirements (10)
    • Ethical Review Standards (10)
    • Open Access Data Sharing (10)
    • Informed Consent Disclosure (10)
    • Ethical Dilemmas in Global Research (10)
  • Protocol Deviation and CAPA Management (50)
    • Major vs Minor Deviations (10)
    • Root Cause Analysis (9)
    • CAPA Documentation (9)
    • Preventive Action Planning (1)
    • Monitoring and Training Based on Deviations (10)
    • Deviation Logs and Tracking Tools (11)
  • Audit Trails and Inspection Readiness (59)
    • TMF and eTMF Audit Trails (10)
    • Audit Trail Reviews in EDC (10)
    • Inspection Preparation Checklists (10)
    • Regulatory Inspection Types (Routine, For-Cause) (10)
    • Responding to Audit Observations (9)
    • Mock Inspections and Readiness Drills (10)
  • Study Feasibility and Site Selection (68)
    • Feasibility Questionnaire Design (10)
    • Site Capability Assessment (11)
    • Historical Performance Review (17)
    • Geographic and Demographic Considerations (10)
    • PI (Principal Investigator) Experience Evaluation (10)
    • Site Activation Planning (10)
  • Outsourcing and Vendor Management (65)
    • Vendor Qualification Process (12)
    • Due Diligence and Risk Assessment (11)
    • Vendor Contract Management (12)
    • KPIs for Vendor Performance (10)
    • Vendor Oversight and Audits (10)
    • Communication and Escalation Plans (10)
  • Remote Monitoring and Virtual Visits (64)
    • Centralized Monitoring Techniques (12)
    • Source Data Review Remotely (12)
    • Virtual Site Visits Protocols (11)
    • eConsent and Remote Data Collection (10)
    • Hybrid Monitoring Models (10)
    • Remote Site Training (9)
  • Laboratory and Sample Management (77)
    • Sample Collection SOPs (10)
    • Sample Labeling and Transport (10)
    • Chain of Custody Documentation (11)
    • Bioanalytical Testing and Storage (15)
    • Central vs Local Labs (11)
    • Laboratory Data Reconciliation (20)
  • Adverse Event Reporting and Management (63)
    • AE vs SAE Differentiation (10)
    • Expedited Reporting Timelines (11)
    • MedDRA Coding of Events (11)
    • AE Data Collection in eCRFs (11)
    • Causality and Severity Assessments (10)
    • Regulatory Reporting Requirements (CIOMS, SUSARs) (10)
  • Interim Analysis and Trial Termination (60)
    • Data Monitoring Committees (DMC) (10)
    • Pre-Specified Stopping Rules (10)
    • Statistical Thresholds for Early Stopping (10)
    • Adaptive Modifications Based on Interim Data (10)
    • Unblinding Protocols (10)
    • Reporting of Early Termination to Regulators (10)

Recent Posts

  • Test
  • Comprehensive Guide to Dental Health Care with Braces
  • Understanding Dental Health Care: Managing Implants Cost Effectively
  • Invisalign Alternatives: Practical Dental Health Care Solutions
  • Practical Guide to Dental Health Care: Managing Braces Effectively

Copyright © 2026 Clinical Research Made Simple.

Powered by PressBook WordPress theme